Bullish
Skye announces cohort review committee approved opening of cohort 2 based on favorable safety data from first four participants treated in cohort 1
Skye Bioscience, Inc. announced that its cohort review committee has approved the opening of cohort 2 for its clinical trial. This decision was made b...
